Classification and characterization of therapeutic antibody aggregates. - Wikidata - awgldk - TriplyDB

Classification and characterization of therapeutic antibody aggregates.

Classification and characterization of therapeutic antibody aggregates.

http://www.wikidata.org/entity/Q30502491

about

Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications Do not drop: mechanical shock in vials causes cavitation, protein aggregation, and particle formation.Directed Evolution of Human Heavy Chain Variable Domain (VH) Using In Vivo Protein Fitness Filter Analysis of antibody aggregate content at extremely high concentrations using sedimentation velocity with a novel interference optics Understanding the relationship between biotherapeutic protein stability and solid-liquid interfacial shear in constant region mutants of IgG1 and IgG4 Flow imaging microscopy for protein particle analysis--a comparative evaluation of four different analytical instruments Rescue of the temperature-sensitive, autosomal-recessive mutation R298S in the sodium-bicarbonate cotransporter NBCe1-A characterized by a weakened dimer and abnormal aggregation.The Use of Index-Matched Beads in Optical Particle Counters.Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.A new approach to quantification of mAb aggregates using peptide affinity probes.EDTA aggregates induce SYPRO orange-based fluorescence in thermal shift assay.Conformational stability and self-association equilibrium in biologics Stabilizing the CH2 Domain of an Antibody by Engineering in an Enhanced Aromatic Sequon Protein particulate detection issues in biotherapeutics development--current status.Immunogenicity of therapeutic proteins: influence of aggregation.Oxidation of therapeutic proteins and peptides: structural and biological consequences.Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools.Comparative Effects of Metal-Catalyzed Oxidizing Systems on Carbonylation and Integrity of Therapeutic Proteins.Overview on biotherapeutic proteins: impact on bioanalysis.Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.Forced degradation studies: current trends and future perspectives for protein-based therapeutics.Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS.A Random Forest Approach for Counting Silicone Oil Droplets and Protein Particles in Antibody Formulations Using Flow Microscopy.Feasibility study of semi-selective protein precipitation with salt-tolerant copolymers for industrial purification of therapeutic antibodies.Why the Immune System Should Be Concerned by Nanomaterials?Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques.The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range.Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc.Effect of growth hormone and IgG aggregates on dendritic cells activation and T-cells polarization.Protein A chromatography increases monoclonal antibody aggregation rate during subsequent low pH virus inactivation hold.Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression.Quantitative laser diffraction method for the assessment of protein subvisible particles AlphaScreen-based homogeneous assay using a pair of 25-residue artificial proteins for high-throughput analysis of non-native IgG.Chemical modifications in therapeutic protein aggregates generated under different stress conditions.Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.

P2860

Q26824543-35D8A7F2-65AF-4218-A409-37948111DD17 Q27333791-A2DC5C13-0A81-4DC7-9FED-CA94848FFEDD Q27684059-CB96721C-0394-4FB3-9FF9-B65DDC767C80 Q28544960-FCF48373-B463-4012-8E38-7F34129F383C Q30357075-A885FBDE-E4AB-4845-9BEC-1406A41D2017 Q31136080-E953DDF4-49A2-48F0-9266-A8E83C6EF4C0 Q35583441-637F282B-C596-4A0A-A110-3AA5BC7D0C6D Q35804399-50A2A7E3-D9C7-47D9-B46D-41CDC7A50CE5 Q36095866-656C97F3-BC3E-43A9-8BB8-832C207AF7DB Q36126960-2960A97E-6D50-492A-85F5-2CA4339CCB78 Q36257660-21E8FE87-9D72-46A6-9210-F110AEDE58EC Q36276715-D5273C04-0301-4A9C-9AD4-649A0E5CC2E2 Q36363131-73F313E0-0C77-4E82-9139-27D3BA11D430 Q36600971-A6570646-4832-45E5-9CB2-141FC1769825 Q36855617-8E644ACB-F922-4BB7-B349-D5B61C6F2212 Q38008257-13C54846-EF4D-40B4-B942-F256EC3FB00D Q38126938-F779A283-40A8-40C1-B3B2-7C47D791C5F3 Q38142887-D5EC899F-314A-44D3-9385-DFFC3346AC42 Q38313350-41A01C9C-6242-40E0-9FDF-E0FB536A34A9 Q38616024-941F6C46-9BFC-4517-8852-37C023CFF008 Q38663214-AAD6E08F-60D2-4940-8F2D-F7115E834F3B Q38665164-39A531FF-AF38-435C-B07F-B71E358062DC Q38798188-EB33CC5B-0156-4B1D-ADCF-ADA4D3DC8BFC Q38855242-BDA7E05A-06AA-49FC-896A-5DC78E6C6C81 Q38982627-7D2EA8E5-03D8-4C5C-9A22-FC33675132E6 Q39084825-23735FD1-C8B8-48F0-8309-D4E427197824 Q39157543-2C301776-8FAF-4B61-8B58-282CED7E773D Q39336982-FC356DF5-CC44-4094-B418-1FD41D28E472 Q40119636-73D1F959-A9B3-4EF3-ACFD-80200D6D2F37 Q40143552-B26F096D-3F3A-4A42-80BD-5EE2C17AF843 Q40206740-0F3BE15B-90DB-44AE-B32E-329C4D04E74C Q40353652-8A3DCD42-EB99-4EED-A08D-446167832A96 Q40514614-3ED8CDFE-8B2C-45EE-8A5C-E5CD13C3B56E Q40566147-729A8370-B288-4471-9422-82B053CA8B7E Q41353938-F0D38504-F211-4CFF-8238-298631861B40 Q41874327-5F61B65B-D6AD-427A-9036-9C005B970926 Q41965705-D8A96D4B-00D0-4595-A074-0DF9C2AC9999 Q42367805-EE8BD15A-2EB7-4E4B-ACF5-2D6BFDF20A5E Q42813806-407EAD14-2C9E-4196-8024-896BB637AA56 Q44285833-CF0FD549-9924-490B-AAC9-14699BA0052D

P2860

Classification and characterization of therapeutic antibody aggregates.

http://www.wikidata.org/entity/Q30502491

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Classification and characterization of therapeutic antibody aggregates.

@ast

Classification and characterization of therapeutic antibody aggregates.

@en

type

label

Classification and characterization of therapeutic antibody aggregates.

@ast

Classification and characterization of therapeutic antibody aggregates.

@en

prefLabel

Classification and characterization of therapeutic antibody aggregates.

@ast

Classification and characterization of therapeutic antibody aggregates.

@en

P1433

Q30502491-9ED57E49-9A1A-4F43-939C-4A82B5781C7B

P1476

Q30502491-124BD573-AEE5-4C7F-947D-FFDDA59BDB55

P2093

Q30502491-43058724-8368-4544-9CFA-807757DB4A4F

Q30502491-A1532552-E224-40A5-AFEA-78DE69DC9599

Q30502491-A7634F80-D736-46BF-9018-770085E337BF

Q30502491-B577A00B-73B6-4E73-8BE6-57CC7E6D09AC

Q30502491-F4C64B0B-EEE6-41AD-87DC-06C5EB2A4CD4

P2860

Q30502491-0582A15D-0CF6-4C3E-84D0-43458065D277

Q30502491-0AC89E0A-AE1E-40A7-8BB8-F90AC28A2BF7

Q30502491-0B6D28EB-1098-41B3-8346-2B5EA393DE5F

Q30502491-15A65260-C663-4AAD-B493-34B5F2A04B37

Q30502491-1DC4C84A-1C85-4881-ACE4-A1061B565C3D

Q30502491-1EFFB95B-C210-48EF-88ED-EBC29DBF2C73

Q30502491-220A77B2-0226-48D8-8D56-AA49CBA29A50

Q30502491-231D0413-6D6F-4E50-861F-250505006AFE

Q30502491-28E0C946-2EA7-42AE-81C0-D76A372A4D8F

Q30502491-298C7CD4-E4CE-40DE-8B6B-E2BD844ADFB0

P304

Q30502491-8832B73C-0CF7-4C0F-A648-E1279F7FD906

P31

Q30502491-34E7565A-9B44-494F-9EA6-EF5D4189D71E

P356

Q30502491-3F9B8091-23BA-4C1F-985B-75CF6CA2C76D

P407

Q30502491-D0055A5B-905C-46E9-82FA-6A88DFB25E9A

P433

Q30502491-8BA98990-7C45-4F4C-9E50-9B90FECBC017

P478

Q30502491-EFB79ABD-64A2-4B3D-9235-B298B558CF0B

P577

Q30502491-C27CFCD0-819C-40A0-A108-3CFE7CB31C98

P698

Q30502491-B56CFFD6-26ED-4A89-B979-BB47AF1C5F95

P921

Q30502491-F1EFB726-C02C-4AB4-8C24-45A3A1EDE9DF

P932

Q30502491-8654101E-DFF7-477D-BAFD-9BDB89816301

P356

JBC.M110.160457

P1433

Journal of Biological Chemistry

P1476

Classification and characterization of therapeutic antibody aggregates.

@en

P2093

Jette Wypych

http://www.w3.org/2001/XMLSchema#string

Linda O Narhi

http://www.w3.org/2001/XMLSchema#string

Marisa K Joubert

http://www.w3.org/2001/XMLSchema#string

Quanzhou Luo

http://www.w3.org/2001/XMLSchema#string

Yasser Nashed-Samuel

http://www.w3.org/2001/XMLSchema#string

P2860

Immunogenicity of protein therapeutics

Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.

Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates.

Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis.

Origin, result and measurement of USP "essentially free" inspection for visible contaminating particles.

Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy.

Pressure provides new insights into protein folding, dynamics and structure.

High hydrostatic pressure as a tool to study protein aggregation and amyloidosis.

Molecular determinants of immunogenicity: the immunon model of immune response

New insights into the mechanisms of protein misfolding and aggregation in amyloidogenic diseases derived from pressure studies.

P304

25118-25133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M110.160457

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

286

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21454532

http://www.w3.org/2001/XMLSchema#string

P921

P932

3137085

http://www.w3.org/2001/XMLSchema#string